Floatz logo

Elesclomol

Fallopian Tube Serous Adenocarcinoma

GOG FoundationSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Fallopian Tube Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
NRG Oncology
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Ohio State University Comprehensive Cancer Center
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 2/3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB

View all 39 →

Same molecule, other indications

Elesclomol is also rated in:

fallopian tube endometrioid adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
fallopian tube clear cell adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
fallopian tube mucinous adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →